Who should be liable for funding recombinant factor VIII?
- PMID: 9564004
- PMCID: PMC1113083
- DOI: 10.1136/bmj.316.7141.1385a
Who should be liable for funding recombinant factor VIII?
Comment on
-
Blood transfusion risk: protecting against the unknown.BMJ. 1998 Mar 7;316(7133):717-8. doi: 10.1136/bmj.316.7133.717. BMJ. 1998. PMID: 9529394 Free PMC article. No abstract available.
References
-
- Metters J. Further precautionary measures on blood products announced. Public Health Link Cascade, Feb 1998.
-
- Green C, Akehurst RL. Recombinant factor VIII versus plasma derived factor VIII in the management of haemophilia A: an examination of the costs and consequences. Sheffield: Trent Institute for Health Services Research, Universities of Leicester, Nottingham, and Sheffield; 1997. (Guidance notes for purchasers 97/04.)
-
- Department of Health. Communicating about risks to public health; pointers to good practice. London: DoH; 1997.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical